How to Play Teladoc Health Stock Post Q3 Results: Buy, Hold or Sell?
Teladoc Health's Q3 results beat estimates, but revenues dipped and losses widened, attributed to soft performance at BetterHelp.
Teladoc Health, Inc. (TDOC) Q3 2025 Earnings Call Transcript
Teladoc Health, Inc. ( TDOC ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Michael Minchak - Vice President of Investor Relations Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Jessica Tassan - Piper Sandler & Co., Research Division Daniel Grosslight - Citigroup Inc. Exchange Research Eduardo Ron - Truist Securities, Inc., Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Brian Tanquilut - Jefferies LLC, Research Division Jack Senft Jeffrey Garro - Stephens Inc., Research Division David Larsen - BTIG, LLC, Research Division Presentation Operator Good afternoon, everyone, and thank you for joining today's Teladoc Health Q3 '25 Earnings Conference Call. My name is Regan, and I will be your moderator today.
Teladoc (TDOC) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates
Teladoc (TDOC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.19 per share a year ago.
Wall Street's Insights Into Key Metrics Ahead of Teladoc (TDOC) Q3 Earnings
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Teladoc (TDOC) Expected to Beat Earnings Estimates: Should You Buy?
Teladoc (TDOC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note
Teladoc (TDOC) concluded the recent trading session at $8.57, signifying a -4.88% move from its prior day's close.
All You Need to Know About Teladoc (TDOC) Rating Upgrade to Buy
Teladoc (TDOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strength Seen in Teladoc (TDOC): Can Its 6.3% Jump Turn into More Strength?
Teladoc (TDOC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
Teladoc Health: Still Struggling To Find A Catalyst
Teladoc Health remains a deep value play at $7, trading at just 5-6x EBITDA, but lacks a clear growth catalyst. Revenue and user metrics are declining across core segments, with BetterHelp and Chronic Care both losing momentum and failing to innovate. Recent acquisitions (UpLift, Catapult Health) have not meaningfully expanded Teladoc's platform or addressed its reliance on basic telehealth connections.
Teladoc Health Earnings: Not Dead Yet
Teladoc's Q2 2025 earnings reaffirm strong free cash flow guidance, with the potential to reach $220 million in the next twelve months. Despite an attractive 7x next year's free cash flow valuation, revenue growth remains stagnant and threatens the bull case. Profitability and an improving balance sheet keep me tepidly bullish, but lack of growth and competitive pressures are major risks.
